Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

atrasentan

Known as: (2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid, 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid, atrasentan [Chemical/Ingredient] 
A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
ABSTRACT Introduction: Diabetic nephropathy (DN) is the leading cause of chronic kidney disease (CKD) and end-stage renal disease… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PURPOSE Circulating tumor cell (CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Despite optimal treatment, including renin-angiotensin system (RAS) inhibitors, patients with type 2 diabetic nephropathy have… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer. Atrasentan… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Although endothelin-receptor antagonists reduce albuminuria in diabetic nephropathy, fluid retention limits their use. Here, we… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Atrasentan is a potent, oral, selective endothelin-A (ET(A)) receptor antagonist that has clinical activity in… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin-A… Expand
Is this relevant?
Review
2003
Review
2003
Collectively, the endothelins and their receptors — referred to as the endothelin (ET) axis — have key physiological functions in… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE To evaluate the efficacy and safety of atrasentan (ABT-627), an endothelin-A receptor antagonist, in the treatment of… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE Endothelin receptors, particularly the ET(A) receptor, have been shown to participate in the pathophysiology of prostate… Expand
Is this relevant?